Clinical trials in Santiago De Compostela – page 22

682 clinical trials in Santiago De Compostela, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Santiago De Compostela at a glance

682

clinical trials

Research sites3

Quick filters

682 trials in Santiago De Compostela

Open in trial search

Metapneumovirus infection

Not yet recruiting

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Investigational

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Investigational

Spain

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:HUMAN METAPNEUMOVIRUS, VIRUS-LIKE PROTEIN
Sponsor:AstraZeneca AB

Contact Research Centre

Psoriasis

Not yet recruiting

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Janssen Cilag International

Contact Research Centre

Efficacy and safety of 6‑grass pollen polymerized extracts 30,000 TU/mL and 10,000 TU/mL in adults with grass pollen‑induced allergic rhinitis/rhinoconjunctivitis, with or without mild‑to‑moderate asthma

Registered drug

Efficacy and safety of 6‑grass pollen polymerized extracts 30,000 TU/mL and 10,000 TU/mL in adults with grass pollen‑induced allergic rhinitis/rhinoconjunctivitis, with or without mild‑to‑moderate asthma

Registered drug

Spain

Participants:0–17 years · 18–64 years
Substances:Bilastine
Sponsor:Inmunotek S.L.

Contact Research Centre

Respiratory syncytial virus immunisation

Not yet recruiting

Safety, Tolerability and Immunogenicity of RSV prefusion F protein 847a and 847b Vaccine in Children 5‑17 Years at High Risk of RSV Disease

Registered drug

Safety, Tolerability and Immunogenicity of RSV prefusion F protein 847a and 847b Vaccine in Children 5‑17 Years at High Risk of RSV Disease

Registered drug

Spain

Participants:0–17 years
Sponsor:Pfizer Inc.

Contact Research Centre

Transitional cell carcinoma+1

Not yet recruiting

Study of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma

Registered drugNo placebo

Study of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Summit Therapeutics Inc.

Contact Research Centre

Group B streptococcus neonatal sepsis

Not yet recruiting

Safety and Immune Response of GBS‑NN/NN2 Vaccine in Pregnant Women and Their Infants to Prevent Group B Streptococcus Infection

Investigational

Safety and Immune Response of GBS‑NN/NN2 Vaccine in Pregnant Women and Their Infants to Prevent Group B Streptococcus Infection

Investigational

Spain

Participants:0–17 years · 18–64 years · Healthy volunteers
Sponsor:Minervax ApS

Contact Research Centre

Small cell lung cancer limited stage

Not yet recruiting

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Pharmacosmos A/S

Contact Research Centre

Choroid melanoma

Not yet recruiting

Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

Investigational

Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Belzupacap Sarotalocan
Sponsor:Aura Biosciences Inc.

Contact Research Centre

Plasma cell myeloma

Not yet recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Varicella+5

Not yet recruiting

Immune response and safety of investigational MMRV vaccine (GSKVX000000025896) drug combination compared with standard MMRV vaccine in healthy children 15 months to 6 years

Registered drugNo placebo

Immune response and safety of investigational MMRV vaccine (GSKVX000000025896) drug combination compared with standard MMRV vaccine in healthy children 15 months to 6 years

Registered drugNo placebo

Spain

Participants:0–17 years · Healthy volunteers
Substances:GSKVX000000025896
Sponsor:GlaxoSmithKline Biologicals

Contact Research Centre

Asthma

Not yet recruiting

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Beclometasone Dipropionate
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Sjogren's syndrome

Not yet recruiting

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Santiago De Compostela

What the registry says about research in the country

01 Respiratory Infections Research

Innovative studies focusing on respiratory viral infections, including trials for RSV, influenza, and COVID-19 vaccines. Research aims to enhance protection in vulnerable populations, particularly adults over 60.

RSV and hMPV vaccine development
Influenza vaccine efficacy studies
COVID-19 vaccine co-administration research

Multiple trials evaluating both single and combination vaccine approaches for respiratory diseases.

02 Cardiovascular Studies

Research targeting cardiovascular health and prevention, with emphasis on innovative treatments for stroke and heart failure. Studies include both therapeutic interventions and preventive measures.

Acute cerebral ischemic stroke treatment
Heart failure prevention strategies
Cardiovascular risk management

Focus on developing new therapeutic approaches for better patient outcomes.

03 Dermatological Research

Advanced clinical investigations in dermatological conditions, particularly focusing on moderate to severe cases of psoriasis and atopic dermatitis.

Plaque psoriasis treatments
Psoriatic arthritis therapies
Atopic dermatitis interventions

Trials evaluating novel therapeutic agents for chronic skin conditions.

Back to Spain All countries